A pilot study to determine the relationship of changes in the characteristics of β1- and β2-adrenoreceptors against the background of the use of β2-agonists with clinically significant parameters in patients with cardiovascular pathology

Abstract

Background: Comorbid cardiovascular and bronchoobstructive diseases worsens disease course and prognosis and causes difficulties in therapy. Effectiveness β2-agonists (cornerstone of bronchoobstructive pathology treatment) depends on β-adrenoreceptors state. Therefore, a detailed study of the functional state of beta-adrenoreceptors is necessary.

Aim: to evaluate the relationship of changes in the characteristics of β1- and β2-adrenoreceptors, against the background of the use of β2-agonists in patients with cardiovascular and bronchoobstructive diseases with clinically significant parameters.

Methods: In the pilot single-center prospective study during 2.5 years 45 patients (15 with cardiovascular and 30 with bronchoobstructive diseases) were included. Anamnestic data and complaints were collected and laboratory and instrumental studies were performed. Modified radioligand analysis on blood T-lymphocytes using radiolabeled Cyanopindolol and unlabeled selective ligands (ICI 118551, CGP 20712) before and after salbutamol and formoterol was performed and the binding activity of β1- and β2-adrenoreceptors was determined.

Results: The correlation analysis between clinically significant parameters and changes in the specific binding index of β1- and β2-adrenoreceptors confirmed its clinical relevance. In test with beta-agonists in cardiovascular and bronchoobstructive diseases patients, an increase in the specific binding index of β1-adrenoreceptors is associated with clinical, laboratory and instrumental parameters of a favorable course of the disease, and an increase in the specific binding index of β2-adrenoreceptors is associated with negative. In the cardiovascular group without bronchoobstructive diseases with salbutamol an increase in the specific binding index of β1-adrenoreceptors was associated with parameters of unfavorable disease course, while an increase in the specific binding index of β2-adrenoreceptors did not have a clear associative relationship with clinical characteristics.

Conclusions: The association of changes in the specific binding index of β1- and β2-adrenoreceptors in patients with cardiovascular and bronchoobstructive diseases with clinically significant parameters during acute tests with short- and long-acting β2-agonists was revealed, which in the future may provide an opportunity to identify patients with an unfavorable course of the disease.

Keywords

cardiovascular diseases / cardiorespiratory pathology / bronchoobstructive diseases / β-adrenergic receptors / β2-agonists

References

[1] André S, Conde B, Fragoso E, et al.; GI DPOC-Grupo de Interesse na Doença Pulmonar Obstrutiva Crónica. COPD and Cardiovascular Disease. Pulmonology. 2019;25(3):168–176. doi: 10.1016/j.pulmoe.2018.09.006

[2] Ingebrigtsen TS, Marott JL, Vestbo J, et al. Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap. BMJ Open Respir Res. 2020;7(1):e000470. doi: 10.1136/bmjresp-2019-000470

[3] Zewari S, Hadi L, van den Elshout F, et al. Obesity in COPD: Comorbidities with practical consequences? COPD. 2018; 15(5):464–471. doi: 10.1080/15412555.2018.1509951

[4] Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: Oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2(10):582–593. doi: 10.1038/ncpneph0283

[5] Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: Dangerous liaisons? Eur Respir Rev. 2018;27(149):180057. doi: 10.1183/16000617.0057-2018

[6] Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med. 2020;41(3):421–438. doi: 10.1016/j.ccm.2020.06.007

[7] Hsu E, Bajaj T. Beta 2 agonists. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.

[8] Liu X, Chen Z, Li S, Xu S. Association of chronic obstructive pulmonary disease with arrhythmia risks: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:732349. doi: 10.3389/fcvm.2021.732349

[9] Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173:1175–1185. doi: 10.1001/jamainternmed.2013.1016

[10] Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD: A meta-analysis. Chest. 2004;125:2309–2321. doi: 10.1378/chest.125.6.2309

[11] Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD. Part 1: Saskatchewan cohort study. Chest. 2012;142:298–304. doi: 10.1378/chest.10-2499

[12] Au DH, Curtis JR, Every NR, et al. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002;121(3):846–851. doi: 10.1378/chest.121.3.846

[13] Агапова О.Ю. Характеристика активности β-адренорецепторов при применении специфических агонистов и антагонистов у пациентов с бронхиальной астмой с сочетанной сердечно-сосудистой патологией: Автореф. дис. … канд. мед. наук. Москва, 2016. 32 с. [Agapova OY. Characteristics of the activity of beta-adrenergic receptors in the use of specific agonists and antagonists in patients with bronchial asthma with combined cardiovascular pathology [dissertation abstract]. Moscow; 2016. 32 p. (In Russ).]

[14] Agapova OY, Skoblov YS, Tkachev GA, et al. Changes in the receptor activity of β2-adrenoreceptors of human T-lymphocytes under the effect of β2-agonists. Mol Biol (Mosk). 2016;50(6):999–1006. doi: 10.7868/S0026898416050025

[15] Смолякова Е.В. Влияние терапии селективным бета1-адреноблокатором и бета2-агонистом на изменение характеристик бета-адренорецепторов у пациентов с кардиореспираторной патологией: Автореф. дис. … канд. мед. наук. Москва, 2019. 28 с. [Smolyakova EV. Effect of therapy with selective beta1-adrenoblocker and beta 2-agonist on the change in the characteristics of beta-adrenergic receptors in patients with cardiorespiratory pathology [dissertation abstract]. Moscow; 2019. 28 p. (In Russ).]

[16] Lang D, Holzem K, Kang C, et al. Arrhythmogenic remodeling of β2 versus β1 adrenergic signaling in the human failing heart. Circ Arrhythm Electrophysiol. 2015;8(2):409–419. doi: 10.1161/CIRCEP.114.002065

[17] Matera MG, Page C, Rinaldi B. β2-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases. Curr Opin Pharmacol. 2018;40:142–146. doi: 10.1016/j.coph.2018.04.012

RIGHTS & PERMISSIONS

Smolyakova E.V., Skoblov Y.S., Skoblova N.A., Rvacheva A.V., Bondarets O.V., Eremenko A.V., Kelekhsaev I.A., Chazova I.E., Zykov K.A.